✦ LIBER ✦

ESPRIT: Interim results from a 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 10-year postmarketing surveillance reg

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Interim results from an open-label exten

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Long-term efficacy and safety of adalimu

✍ Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H. Sasso 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Impact of adalimumab treatment on health

✍ D. Revicki; M.K. Willian; J.-H. Saurat; K.A. Papp; J.-P. Ortonne; C. Sexton; A. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

Efficacy and safety results from a rando

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB